MiR-214 prevents the progression of diffuse large B-cell lymphoma by targeting PD-L1
Jing-Ran Sun1, Xiao Zhang2, Ya Zhang3
1Liaocheng Central Blood Station, 75 Huashan Road, Liaocheng, Shandong 25200 People's Republic of China.
Objective:
We explored the role and mechanism of miR-214 involvement in the progression of diffuse large B-cell lymphoma (DLBCL).
Methods:
The expression levels of miR-214 and PD-L1 in human DLBCL cell lines and in tissue samples from patients with DLBCL were determined using quantitative RT-PCR. The dual-luciferase reporter assay was employed to determine the correlation between the expressions of miR-214 and PD-L1. Cell viability, invasiveness and apoptosis were respectively examined in cells of the DLBCL line OCI-Ly3 using CCK-8, transwell and flow cytometry assays. The expression level of PD-L1 was determined via immunoblotting. Inflammatory cytokine secretion was determined via enzyme-linked immune sorbent assay (ELISA).
Results:
miR-214 was downregulated and PD-L1 was upregulated in DLBCL tissues and cell lines in comparison to normal adjacent tissues or normal B-cell. This indicates a negative correlation in the expression levels. Overexpression of miR-214 inhibited cell viability and invasion and induced apoptosis of OCI-Ly3 cells. Moreover, miR-214 was shown to target PD-L1 mRNA by binding to its 3'-untranslated region (UTR). Knockdown of PD-L1 attenuated the malignant phenotype of OCI-Ly3 cells. Overexpression of miR-214 inhibited tumor growth by targeting PD-L1 in vivo.
Conclusion:
By targeting PD-L1, miR-214 regulates the progression of DLBCL in vitro and in vivo.
